United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $518.03, for a total value of $4,921,285.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares in the company, valued at $67,343.90. This trade represents a 98.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Performance

UTHR opened at $535.81 on Wednesday. The business’s 50-day simple moving average is $483.83 and its 200-day simple moving average is $457.40. The company has a market cap of $23.48 billion, a P/E ratio of 19.20, a PEG ratio of 1.91 and a beta of 0.84. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $548.12.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the firm earned $6.19 EPS. The company’s revenue was up 7.4% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the subject of several research reports. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Royal Bank Of Canada increased their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. TD Cowen raised their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $539.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new position in United Therapeutics during the 4th quarter worth approximately $31,000. Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics during the 4th quarter worth approximately $48,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.